PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2025

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-/HR+), and triple negative breast cancer (TNBC). The prognoses of HER2-/HR+ and TNBC differ dramatically, as patients with TNBC progress more rapidly towards metastatic disease and only respond to chemotherapy agents. A large number of pipeline agents are being developed in HER2-/HR+ and/or TNBC, and are likely to change the treatment paradigm for these patients.

This report highlights the significant unmet need for expansion in the HER2- breast cancer marker across the eight major markets; it also discusses the associated commercial opportunities for new market entrants to gain a foothold in the market. GlobalData anticipates the HER2- breast cancer market to almost double, from $5.43B to $10.58B, over the forecast period of 2015-2025. The key drivers will be the incorporation of CDK4/6 inhibitors into the first-line metastatic setting and the rise of new targeted therapies and immunotherapies.

Scope

Overview of HER2- breast cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, treatment guidelines and disease management.

Annualized HER2- breast cancer therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2015 and forecast for seven years to 2025.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HER2- breast cancer therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of middle- to late-stage pipeline drugs.

Analysis of the current and future market competition in the global HER2- breast cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

In HER2-/HR+ breast cancer, the recent launch of CDK4/6 inhibitors in the US market has changed the paradigm of treatment in metastatic setting in these patients. How will new late-stage drugs will be positioned in comparison to the CDK 4/6 inhibitor Ibrance (palbociclib)? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

Chemotherapy agents used in breast cancer are mostly well-established generics used in combination or as monotherapy. How will the advent of new therapies change the drug treatment landscape for HER2-negative breast cancer?

Several new late-stage agents target specific patients population. How will these agents will compete against chemotherapies in terms of efficacy and market size?

Companies mentioned

AbbVie

Array BioPharma

Astellas Pharma

AstraZeneca

Bayer

Celgene

Celldex

Chipscreen Biosciences

Eisai

Eli Lilly

Genentech

Immunomedics

Innocrin Pharmaceuticals

Medivation

Merck & Co

NewLink Genetics

Novartis ...

AbbVie

Array BioPharma

Astellas Pharma

AstraZeneca

Bayer

Celgene

Celldex

Chipscreen Biosciences

Eisai

Eli Lilly

Genentech

Immunomedics

Innocrin Pharmaceuticals

Medivation

Merck & Co

NewLink Genetics

Novartis

OncoMed Pharmaceuticals

Pfizer

Roche

R-PHARM

Syndax Pharmaceuticals

Tesaro

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology ...

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.1.3Basic Breast Anatomy

3.2Disease Classification/Staging Systems

3.3Symptoms

3.4Prognosis

3.5Quality of Life

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.3.1US

4.3.25EU

4.3.3Japan

4.3.4China (Urban)

4.3.5Prevalence and Survival

4.4Forecast Methodology

4.4.1Sources Used Tables

4.4.2Forecast Assumptions and Methods

4.4.3Sources Not Used

4.5Epidemiological Forecast for Non-Invasive DCIS Breast Cancer (2015–2025)

4.5.1Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer

4.5.2Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status

4.6Epidemiological Forecast for Invasive Breast Cancer (2015–2025)

4.6.1Diagnosed Incident Cases of Invasive Breast Cancer

4.6.2Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer

4.6.3Age-Standardized Diagnosed Incidence of Invasive Breast Cancer

4.6.4Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer

4.6.5Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis

4.6.6Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status

4.6.7Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Menopausal Status, and Site of Metastasis

4.6.8Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Stage at Diagnosis, Menopausal Status, and Type of Biomarker Expression

4.6.9Diagnosed Incident Cases of TN Breast Cancer by Stage at Diagnosis and BRCA Expression

4.7Discussion

4.7.1Epidemiological Forecast Insight

4.7.2Limitations of the Analysis

4.7.3Strengths of the Analysis

5Disease Management

5.1Diagnosis and Treatment Overview

5.1.1Screening and Diagnosis

5.1.2Treatment Overview of Loco-Regional Breast Cancer

5.1.3Neoadjuvant and Adjuvant Treatment Regimen

5.1.4Treatment of Metastatic HR+ Disease

5.1.5Treatment of Metastatic TNBC

5.1.6Treatment Guidelines and Leading Prescribed Drugs

5.2US

5.2.1Diagnosis

5.2.2Clinical Practice

5.3France

5.3.1Diagnosis

5.3.2Clinical Practice

5.4Germany

5.4.1Diagnosis

5.4.2Clinical Practice

5.5Italy

5.5.1Diagnosis

5.5.2Clinical Practice

5.6Spain

5.6.1Diagnosis

5.6.2Clinical Practice

5.7UK

5.7.1Diagnosis

5.7.2Clinical Practice

5.8Japan

5.8.1Diagnosis

5.8.2Clinical Practice

5.9China

5.9.1Diagnosis

5.9.2Clinical Practice

6Competitive Assessment

6.1Overview

6.2Product Profiles (Branded Therapies)

6.2.1Ibrance (palbociclib)

6.2.2Abraxane (nab-paclitaxel)

6.2.3Afinitor (everolimus)

6.2.4Avastin (bevacizumab)

6.2.5Halaven (eribulin mesylate)

6.2.6Ixempra (ixabepilone)

6.2.7Faslodex (fulvestrant)

6.2.8Doxil/Caelyx (pegylated liposomal doxorubicin)

6.3Product Profiles (Hormonal Agents)

6.3.1Tamoxifen

6.3.2Aromatase Inhibitors

7Unmet Needs and Opportunities

7.1Overview

7.1.1Defined Treatment Plan for BRCA+ Patients and the Prevention of Prophylactic Surgeries

7.1.2Targeted Treatment Options for Triple Negative Breast Cancer Patients

7.1.3Treatment of Brain Metastasis

7.1.4For HR+ Patients, Reduced Resistance to Hormonal Agents

7.1.5Improved Convenience of Administration of Hormonal Agents

8Pipeline Assessment

8.1Overview

8.2CDK4/6 inhibitors

8.2.1Abemaciclib (LY2835219)

8.2.2Ribociclib (LEE011)

8.3Poly ADP-Ribose Polymerase Inhibitors

8.3.1Lynparza (olaparib)

8.3.2Talazoparib (BMN 673)

8.3.3Veliparib (ABT-888)

8.3.4Niraparib (MK4827)

8.4Phosphoinositide 3 Kinase Inhibitors

8.4.1Buparlisib (BKM- 120)

8.4.2Alpelisib (BYL-719)

8.4.3Taselisib (GDC-0032)

8.5PD-1/PD-L1 Checkpoint Inhibitors

8.5.1Tecentriq (atezolizumab)

8.5.2Keytruda (pembrolizumab)

8.6Histone Deacetylase Inhibitors

8.6.1Entinostat

8.6.2Epidaza (chidamide)

8.7Antibody Drug Conjugates

8.7.1Sacituzimab govitecan (IMMU-132)

8.7.2Glembatumumab vedotin (CDX-011)

8.8Others

8.8.1Xtandi (enzalutamide)

8.9Promising Drugs in Early Stage Clinical Development

8.9.1Seviteronel

8.9.2Ipatasertib

8.9.3Vanctitumab

8.9.4IDO Checkpoint Inhibitors

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles

9.3.1Pfizer

9.3.2Novartis

9.3.3Roche

9.3.4AstraZeneca

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2US

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.35EU

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Japan

10.4.1Forecast

10.4.2Key Events

10.4.3Drivers and Barriers

10.5China

10.5.1Forecast

10.5.2Key Events

10.5.3Drivers and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Diagnosed Patients with HER2- Breast Cancer

11.4.2Percent Drug-Treated Patients

11.4.3Drugs Included in Each Therapeutic Class

11.4.4Launch and Patent Expiration Dates

11.4.5General Pricing Assumptions

11.4.6Average Body Weight and Surface Area Across the 8MM

11.4.7General Forecast Assumptions

11.4.8Individual Drug Assumptions

11.4.9TS-1 Assumptions

11.4.10Generic Erosion

11.4.11Pricing of Pipeline Agents

11.5Primary Research – Key Opinion Leaderss Interviewed for This Report

11.6Primary Research – High-Prescribers Surveyed for this Report

11.7About the Authors

11.7.1Author

11.7.2Epidemiologist

11.7.3Therapy Director

11.7.4Epidemiology Director

11.7.5Global Director of Therapy Analysis and Epidemiology

11.8About GlobalData

11.9Disclaimer

List of tables

Table 1: Molecular Subtypes of Breast Cancer

Table 2: AJCC Stage Definitions for Breast Cancer

Table 3: Prognosis for Breast Cancer

Table 4: Risk Factors ...

Table 1: Molecular Subtypes of Breast Cancer

Table 2: AJCC Stage Definitions for Breast Cancer

Table 3: Prognosis for Breast Cancer

Table 4: Risk Factors and Comorbidities for Breast Cancer

Table 5: 8MM, Most Recent Five-Year Relative Survival for Invasive Breast Cancer, Women (%)

Table 6: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Non-Invasive DCIS Breast Cancer

Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status

Table 8: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Invasive Breast Cancer

Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Invasive Breast Cancer by HER2 Status

Table 10: 8MM, Sources of Epidemiological Data Used to Forecast the Relative Survival of Invasive Breast Cancer

Table 11: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Stage at Diagnosis

Table 12: 8MM, Sources of Epidemiological Data Used to Forecast HER2-, HR+ Invasive Breast Cancer by Stage at Diagnosis

Table 13: 8MM, Sources of Epidemiological Data Used to Forecast TN Invasive Breast Cancer by Stage at Diagnosis

Table 14: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Menopausal Status

Table 15: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Site of Metastasis

Table 16: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Type of Biomarker Expression

Table 17: 8MM, Sources Not Used in Epidemiological Analysis of Breast Cancer

Table 18: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025

Table 19: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015

Table 20: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025

Table 21: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N (Row %), 2015

Table 22: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025

Table 23: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, N, 2015

Table 24: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015

Table 25: Treatment Guidelines for HER2- Breast Cancer

Table 26: Most Prescribed Regimens for HER2- Breast Cancer by Drug Class in the Global Markets, 2015

Table 27: Country Profile – US

Table 28: Country Profile – France

Table 29: Country Profile – Germany

Table 30: Country Profile – Italy

Table 31: Country Profile – Spain

Table 32: Country Profile – UK

Table 33: Country Profile – Japan

Table 34: Country Profile – China

Table 35: Product Profile – Ibrance

Table 36: Summary of the Results of the PALOMA-2 Trial

Table 37: Summary of the Results of the PALOMA-3 Trial

Table 38: Safety profile of Ibrance + letrozole

Table 39: Safety Profile of Ibrance in Combination with Faslodex

Table 40: Ibrance SWOT Analysis, 2016

Table 41: Product Profile – Abraxane

Table 42: Efficacy of Abraxane

Table 43: Safety Profile of Abraxane

Table 44: Abraxane SWOT Analysis, 2016

Table 45: Product Profile – Afinitor (everolimus)

Table 46: Efficacy of Afinitor in Second-Line HER2-/HR+ Advanced Breast Cancer

Table 47: Safety Profile of Afinitor

Table 48: Afinitor SWOT Analysis, 2016

Table 49: Product Profile – Avastin

Table 50: Efficacy of Avastin in First Line Metastatic Breast Cancer

Table 51: Safety of Avastin in First-Line Metastatic Breast Cancer

Table 52: Avastin SWOT Analysis, 2016

Table 53: Product Profile – Halaven

Table 54: Efficacy of Halaven

Table 55: Safety Profile of Halaven

Table 56: Halaven SWOT Analysis, 2016

Table 57: Product Profile – Ixempra

Table 58: Efficacy of Ixempra Monotherapy

Table 59: Efficacy of Ixempra in Combination with Xeloda

Table 60: Safety Profile of Ixempra

Table 61: Ixempra SWOT Analysis, 2016

Table 62: Product Profile – Faslodex

Table 63: Efficacy of Faslodex in the First Line

Table 64: Efficacy of Faslodex Monotherapy in the Second Line

Table 65: Efficacy of Faslodex in the First Line

Table 66: Safety of Faslodex in the First Line

Table 67: Safety of Faslodex in the Second Line

Table 68: Faslodex SWOT Analysis, 2016

Table 69: Product Profile – Doxil

Table 70: Doxil SWOT Analysis, 2016

Table 71: Product Profile – Nolvadex/Soltamox

Table 72: AI Approvals in the 8MM

Table 73: Unmet Need and Opportunity in HER2- Breast Cancer

Table 74: Product Profile – Abemaciclib (LY2835219)

Table 75: Efficacy of Abemaciclib in Monotherapy in Pretreated HER2-/HR+ Metastatic Breast Cancer Patients (MONARCH 1 NCT02102490)

Table 76: Safety of Abemaciclib in Monotherapy in Pretreated HER2-/HR+ Metastatic Breast Cancer Patients

Table 77: Abemaciclib SWOT Analysis, 2016

Table 78: Product Profile – Ribociclib

Table 79: Efficacy of Ribociclib in Combination with Letrozole in HER2-/HR+ Metastatic Breast Cancer Patients (MONALEESA 2, NCT01958021)

Table 80: Most Common AEs of Ribociclib in Combination with Letrozole in HER2-/HR+ Metastatic Breast Cancer Patients (MONALEESA 2, NCT01958021)

Table 81: Ribociclib SWOT Analysis, 2015

Table 82: Product Profile – Lynparza

Table 83: Summary of the Results of the ICEBERG 1 Phase II Trial (NCT00494234)

Table 84: Summary of the Most Commonly Reported AEs, Occurring in at Least 20% of Patients With Advanced Ovarian Cancers Treated with Lynparza Monotherapy

Table 85: Lynparza SWOT Analysis, 2016

Table 86: Product Profile – Talazoparib

Table 87: Summary of the Most Commonly Reported AEs in Patients Treated with Talazoparib Monotherapy

Table 88: Talazoparib SWOT Analysis, 2016

Table 89: Product Profile – Veliparib

Table 90: Veliparib SWOT Analysis, 2016

Table 91: Product Profile – Niraparib

Table 92: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Niraparib

Table 93: Niraparib SWOT Analysis 2016

Table 94: Product Profile – Buparlisib (BKM-120)

Table 95: Summary of the Results of the Trial of Buparlisib + Faslodex vs. Faslodex

Table 96: Summary of AEs From the Trial of Buparlisib + Faslodex vs. Faslodex

Table 97: Buparlisib SWOT Analysis

Table 98: Product Profile – Alpelisib (BYL- 719)

Table 99: Summary of the Results of the Alpelisib Trial

Table 100: Summary of AEs from the Trial of Alpelisib

Table 101: Alpelisib SWOT Analysis

Table 102: Product Profile – Taselisib (GDC-0032)

Table 103: Summary of the Results of the Taselisib Trial

Table 104: Summary of the Safety of Taselisib

Table 105: Taselisib SWOT Analysis

Table 106: Product Profile – Tecentriq

Table 107: Summary of the Results of the Phase Ib Trial of Tecentriq in Combination with Abraxane in Patients with mTNBC (Genetech, NCT01633970)

Table 108: Summary of AEs from the Phase Ib Trial of Tecentriq + Abraxane in Patients with mTNBC (Genetech, NCT01633970)

Table 109: Tecentriq SWOT Analysis, 2016

Table 110: Product Profile – Keytruda (Pembrolizumab)

Table 111: Summary of the Results of Keytruda in HER2-/HR+ Patients in the KEYNOTE-028 Trial (MSD, NCT02054806)

Table 112: Summary of AEs of All Grades for Keytruda in HER2-/HR+ Patients in the Keytruda KEYNOTE-028 Trial (MSD, NCT02054806)

Table 113: Summary of Grade 3-4 AEs from the Trial of Keytruda (MSD, NCT02054806)

Table 114: Keytruda SWOT Analysis, 2016

Table 115: Product Profile – Entinostat

Table 116: Efficacy Results from the ENCORE301 Trial of Exemestane + Entinostat vs. Exemestane + Placebo

Table 117: Most Commonly Reported AEs from the ENCORE301 trial of Exemestane + Entinostat vs. Exemestane + Placebo

Table 118: Entinostat SWOT, 2016

Table 119: Product Profile – Epidaza

Table 120: Most Commonly Reported AEs from the Phase II Trial of Epidaza + Exemestane

Table 121: Epidaza SWOT Analysis

Table 122: Product Profile – Sacituzumab Govitecan

Table 123: Summary of the Results of Sacituzimab Govitecan Phase I/II Trial in Metastatic TNBC (Immunomedics Inc., NCT01631552)

Table 124: Summary of AEs from the Phase I/II Trial of Sacituzimab Govitecan (Immunomedics Inc., NCT01631552)

Table 125: Sacituzimab Govitecan SWOT, 2016

Table 126: Product Profile – Glembatumumab vedotin

Table 127: Efficacy Results of the Phase IIb EMERGE Trial of Glembatumumab Vedotin Monotherapy in Metastatic TNBC (NCT01156753)

Table 128: Safety Results of the Phase IIb EMERGE Trial of Glembatumumab Vedotin Monotherapy in Solid Tumors

Table 129: Glembatumumab Vedotin SWOT, 2016

Table 130: Product Profile – Xtandi

Table 131: Summary of the Results of ENZA Phase II Xtandi Trial (NCT01889238)

Table 132: Summary of the Results of Xtandi Trial

Table 133: Xtandi SWOT Analysis, 2016

Table 134: Early Stage Clinical Development in HER2- Breast Cancer

Table 135: Key Companies in the Disease HER2- Breast Cancer Market in the 8MM, 2015

Table 136: Pfizer’s HER2- Metastatic Breast Cancer Portfolio Assessment, 2016

Table 137: Novartis’ HER2- Metastatic Breast Cancer Portfolio Assessment, 2016

Table 138: Roche’s HER2- Breast Cancer Portfolio Assessment, 2016

Table 139: AZ’s HER2- Breast Cancer Portfolio Assessment, 2016

Table 140: Global HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025

Table 141: Key Events Impacting Sales for HER2-/HR+ in the US, 2015–2025

Table 142: Key Events Impacting Sales for TNBC in the US, 2015–2025

Table 143: US HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025

Table 144: Key Events Impacting Sales for HER2-/HR+ Breast Cancer in the 5EU, 2015–2025

Table 145: Key Events Impacting Sales for TNBC in the 5EU, 2015–2025

Table 146: 5EU HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025

Table 147: Key Events Impacting Sales for HER2-/HR+ breast cancer in Japan, 2015–2025

Table 148: Key Events Impacting Sales for TNBC in Japan, 2015–2025

Table 149: Japanese HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025

Table 150: Key Events Impacting Sales for HER2-/HR+ Breast Cancer in China, 2015–2025

Table 151: Key Events Impacting Sales for TNBC in China, 2015–2025

Table 152: Chinese HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025

Table 153: Key Launch Dates in HER2- Breast Cancer

Table 154: Key Patent Expiries

Table 155: Average Body Weight and Surface Area Across the 8MM

Table 156: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of figures

Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes

Figure 2: 8MM, Crude Diagnosed Incidence Rates of Invasive Breast Cancer, Ages =18 Years, Women, Cases ...

Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes

Figure 2: 8MM, Crude Diagnosed Incidence Rates of Invasive Breast Cancer, Ages =18 Years, Women, Cases per 100,000 Population, 2005?2014

Figure 3: Case Flow Map

Figure 4: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages =18 Years, Selected Years, 2015–2025

Figure 5: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages =18 Years, 2015

Figure 6: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, Selected Years, 2015–2025

Figure 7: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, 2015

Figure 8: 8MM, Age-Standardized Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, 2015

Figure 9: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages =18 Years, Select Years, 2015–2025

Figure 10: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 11: 8MM, Diagnosed Incident Cases of Breast Cancer by HER2 Status, Women, Ages =18 Years, 2015

Figure 12: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 13: 8MM, Proportion of HER2+/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015

Figure 14: 8MM, Proportion of HER2+/HR- Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015

Figure 15: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Site of Metastasis, Women, Ages =18 Years, 2015

Figure 16: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 17: 8MM, Proportion of HER2-/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015

Figure 18: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Type of Biomarker Expression, Women, Ages =18 Years, 2015

Figure 19: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 20: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer with BRCA Expression, Women, Ages =18 Years, 2015

Figure 21: Overview of Non-Invasive and Invasive Breast Cancer Treatment

Figure 22: Neoadjuvant/Adjuvant Settings Treatment Paradigm in HER2- Breast Cancer

Figure 23: Key Late-Stage Key Clinical Trials of Ibrance

Figure 24: Key Late-Stage Key Clinical Trials of Abraxane

Figure 25: Key Late-Stage Key Clinical Trials of Afinitor

Figure 26: Key Late-Stage Clinical Trials of Avastin

Figure 27: Key Late-Stage Clinical Trials of Halaven

Figure 28: Key Late-Stage Clinical Trials of Ixempra

Figure 29: Key Late-Stage Clinical Trials of Faslodex

Figure 30: Late-Stage Clinical Trials of Drugs in HR+ Breast Cancer

Figure 31: Late-Stage Clinical Trials of Drugs in TNBC

Figure 32: Key Late-Stage Clinical Trials of Abemaciclib

Figure 33: Clinical and Commercial Positioning of Abemaciclib

Figure 34: Key Late-Stage Clinical Trials of Ribociclib

Figure 35: Clinical and Commercial Positioning of Ribociclib

Figure 36: Key Late-Stage Clinical Trials of Lynparza

Figure 37: Clinical and Commercial Positioning of Lynparza

Figure 38: Key Late-Stage Clinical Trials of Talazoparib

Figure 39: Clinical and Commercial Positioning of Talazoparib

Figure 40: Key Late-Stage Clinical Trials of Veliparib

Figure 41: Clinical and Commercial Positioning of Veliparib

Figure 42: Key Late-Stage Clinical Trials of Niraparib

Figure 43: Clinical and Commercial Positioning of Niraparib

Figure 44: Key Late-Stage Clinical Trials of Buparlisib

Figure 45: Clinical and Commercial Positioning of Buparlisib

Figure 46: Key Late-Stage Clinical Trials of Alpelisib

Figure 47: Clinical and Commercial Positioning of Alpelisib

Figure 48: Key Late-Stage Clinical Trials of Taselisib

Figure 49: Clinical and Commercial Positioning of Taselisib

Figure 50: Key Late-Stage Clinical Trials of Tecentriq

Figure 51: Clinical and Commercial Positioning of Tecentriq

Figure 52: Key Late-Stage Clinical Trials of Keytruda

Figure 53: Clinical and Commercial Positioning of Keytruda

Figure 54: Key Late-Stage Clinical Trials of Entinostat

Figure 55: Clinical and Commercial Positioning of Entinostat

Figure 56: Key Late-Stage Clinical Trials of Epidaza

Figure 57: Clinical and Commercial Positioning of Epidaza

Figure 58: Key Late-Stage Clinical Trials of Sacituzumab Govitecan

Figure 59: Clinical and Commercial Positioning of sacituzimab govitecan

Figure 60: Key Late-Stage Clinical Trials of Glembatumumab Vedotin

Figure 61: Clinical and Commercial Positioning of Glembatumumab Vedotin

Figure 62: Key Late-Stage Clinical Trials of Xtandi

Figure 63: Clinical and Commercial Positioning of Xtandi

Figure 64: Global Sales of Branded Products for HER2- Breast Cancer by Company, 2015 and 2025

Figure 65: Company Portfolio Gap Analysis in HER2- Breast Cancer, 2015–2025

Figure 66: Pfizer SWOT Analysis in HER2- Metastatic Breast Cancer, 2016

Figure 67: Novartis SWOT Analysis in HER2- Metastatic Breast Cancer, 2016

Figure 68: Roche SWOT Analysis in HER2- Metastatic Breast Cancer, 2016

Figure 69: Roche SWOT Analysis in HER2- Metastatic Breast Cancer, 2016

Figure 70: Global Sales ($M) for HER2- Breast Cancer by Region, 2015–2025

Figure 71: Global Sales for HER2- Breast Cancer by Drug, 2015–2025

Figure 72: Sales for HER2-/HR+ Breast Cancer in the US by Drug, 2015–2025

Figure 73: Sales for TNBC Breast Cancer in the US by Drug, 2015–2025

Figure 74: Sales for HER2-/HR+ Breast Cancer in the 5EU by Drug, 2015–2025

Figure 75: Sales for TNBC Breast Cancer in the 5EU by Drug, 2015–2025

Figure 76: Sales for HER2-/HR+ Breast Cancer in Japan by Drug, 2015–2025

Figure 77: Sales for TNBC Breast Cancer in Japan by Drug, 2015–2025

Figure 78: Sales for HER2-/HR+ Breast Cancer in China by Drug, 2015–2025

Figure 79: Sales for TNBC Breast Cancer in China by Drug, 2015–2025

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports